APA (7th ed.) Citation

Sarkozy, C., Chartier, L., Ribrag, V., Gressin, R., Geisler, C. H., Kluin-Nelemans, H. C., . . . Cheminant, M. (2025). Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA study. Blood Cancer Journal, 15(1), . https://doi.org/10.1038/s41408-025-01241-9

Chicago Style (17th ed.) Citation

Sarkozy, Clémentine, et al. "Validation of POD24 as a Robust Early Clinical Indicator of Poor Survival in Mantle Cell Lymphoma from 1280 Patients on Clinical Trials, a LYSA Study." Blood Cancer Journal 15, no. 1 (2025). https://doi.org/10.1038/s41408-025-01241-9.

MLA (9th ed.) Citation

Sarkozy, Clémentine, et al. "Validation of POD24 as a Robust Early Clinical Indicator of Poor Survival in Mantle Cell Lymphoma from 1280 Patients on Clinical Trials, a LYSA Study." Blood Cancer Journal, vol. 15, no. 1, 2025, https://doi.org/10.1038/s41408-025-01241-9.